# BOTOX® vs. XEOMIN® for Chronic Migraine

> **NCT05598723** · PHASE3 · RECRUITING · sponsor: **Naval Medical Center Camp Lejeune** · enrollment: 128 (estimated)

## Conditions studied

- Chronic Migraine

## Interventions

- **DRUG:** IncobotulinumtoxinA (XEOMIN®)
- **DRUG:** OnabotulinumtoxinA (BOTOX®)

## Key facts

- **NCT ID:** NCT05598723
- **Lead sponsor:** Naval Medical Center Camp Lejeune
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-24
- **Primary completion:** 2026-02-24
- **Final completion:** 2026-08-24
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598723, "BOTOX® vs. XEOMIN® for Chronic Migraine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05598723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*